Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan vs Valsartan in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy (VIVALDI)
NCT00153023Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2003
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 4, randomised, double-blind trial of telmisartan in diabetic nephropathy (DN) and hypertension (HTN) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in 24 hour proteinuria at 1 year. Started Apr 2003; status: completed.
02
Drugs
telmisartan
03
Conditions
diabetic nephropathy (DN)hypertension (HTN)
Beyond the preview
Go deeper on NCT00153023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00153023.